Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 13, 2026The Journal of Prevention of Alzheimer s DiseaseOpen Access

Relative importance of blood-based biomarkers for Alzheimer’s disease-specific neurodegeneration and cognitive decline

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKeun You KimHHHyunsun HamEYEun Jin Yoon

Discussion

Loading...

Member takes

Overview

Randomized trial examines blood biomarkers for neurodegeneration in Alzheimer’s disease, suggesting tailored strategies based on amyloid status.

Key Points

  • This study aims to identify the most effective blood-based biomarkers for diagnosing Alzheimer’s disease-specific neurodegeneration and cognitive decline.
  • Analyzed cross-sectional data from two cohorts with a total of 434 participants: SAMD (150 Asian) and ADNI (284 White).
  • Quantified plasma biomarker levels using Single-Molecule Array (Simoa) assays.
  • Conducted dominance analysis to evaluate contributions of biomarkers to brain region thickness and cognitive performance, adjusted for relevant demographics.
  • GFAP and p-tau217 were dominant predictors of neurodegeneration and cognitive impairment in amyloid-positive participants.
  • P-tau217 showed superior performance in explaining total cognition and memory in the amyloid-positive group.
  • Among amyloid-negative participants, NfL outperformed GFAP in predicting neurodegeneration and cognitive decline.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a548219475c38bf615a5bf0https://doi.org/10.1016/j.tjpad.2026.100644
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plasma P‐tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline2025 · 17 citations
  2. 2Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic2025 · 17 citations
  3. 3Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia2024 · 39 citations
  4. 4Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort study2025 · 5 citations
  5. 5Plasma phosphorylated tau-217 correlates with brain atrophy, cognition, and cerebrospinal fluid biomarkers in a cognitively healthy community cohort2025 · 8 citations